5 Small-cap Biotech ETFs to Watch
Because of exchange-traded funds (ETFs), buyers don’t must be tied to at least one particular inventory. Relating to biotech ETFs, they provide sector members publicity to many biotech firms through one automobile.
ETFs are a preferred selection as they permit buyers to enter the market extra safely in comparison with investing in standalone shares. A key benefit is that even when one firm within the ETF takes a success, the affect might be much less direct.
Under the Investing Information Community takes a take a look at 5 small-cap biotech ETFs. The funds had been chosen utilizing ETFdb.com, and their complete belongings beneath administration (AUM) had been beneath US$100 million as of Could 20, 2025.
All different figures had been additionally present as of that date. Learn on to study extra about these funding autos.
3. Tema GLP-1 Weight problems and Cardiometabolic ETF (NASDAQ:HRTS)
AUM: US$51.5 million
Launched in November 2023, the Tema GLP-1 Weight problems and Cardiometabolic ETF tracks biotech shares with a concentrate on diabetes, weight problems and cardiovascular ailments. The fund was renamed on March 25 from Tema Cardiovascular and Metabolic ETF. Greater than three-quarters of its holdings are based mostly within the US.
There are 47 holdings on this biotechnology fund, with about 75 p.c being large-cap shares and 18 p.c mid-cap. Its high holdings are Eli Lilly and Firm at a 9.92 p.c weight, Abbott Laboratories (NYSE:ABT) at 4.77 p.c and AstraZeneca (NASDAQ:AZN) at 4.14 p.c.
That is an up to date model of an article initially printed by the Investing Information Community in 2015.
Don’t neglect to observe us @INN_LifeScience for real-time information updates!
Securities Disclosure: I, Meagen Seatter, maintain no direct funding curiosity in any firm talked about on this article.
From Your Website Articles
Associated Articles Across the Internet
